Ascentage Pharma Presents Preclinical Data for Olverembatinib, APG-2449, and APG-5918 at AACR 2026

Ascentage Pharma (NASDAQ: AAPG) announced the presentation of four preclinical studies at the American Association for Cancer Research (AACR) 2026 Annual Meeting. The studies highlight the potential of three drug candidates in various combination therapies. First, olverembatinib (HQP1351), an approved BCR-ABL inhibitor in China, showed synergistic effects with chemotherapy in endometrial carcinoma (EC) models and with acalabrutinib in mantle cell lymphoma (MCL) models. Second, APG-2449, a FAK/ALK/ROS1 inhibitor, demonstrated enhanced antitumor activity when combined with dabrafenib and trametinib in BRAF V600E-mutant colorectal cancer and melanoma models by addressing resistance mechanisms. Finally, APG-5918, an EED inhibitor, showed synergy with topoisomerase I inhibitors in small-cell lung cancer (SCLC) models through epigenetic priming. These findings are intended to inform the company's clinical development strategies and complement ongoing global registrational trials. Olverembatinib, APG-2449, and APG-5918 remain investigational and are not yet FDA-approved.